Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease
activity in participants with systemic lupus erythematosus (SLE) with active cutaneous
manifestations and joint involvement (Part A), and in participants with active cutaneous
lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE,
including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part
B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in
reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of
BIIB059 (Parts A and B).